Tivanisiran clinical trials
Also written SYL1001.
How each study uses tivanisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2011 (1)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Studies
Open first, then newest update. How each study uses tivanisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Safety Study of Tivanisiran to Treat Dry EyeCompletedPhase 3Sylentis, S.A.NCT05310422Written as Tivanisiran sodium ophthalmic solution
- Tivanisiran for Dry Eye in Subjects With Sjögren's SyndromeCompletedPhase 3Sylentis, S.A.NCT04819269Written as Tivanisiran sodium ophthalmic solution
- HELIX, a Double-masked Study of SYL1001 in Patients With Moderate to Severe Dry Eye Disease (DED)CompletedPhase 3Sylentis, S.A.NCT03108664Written as SYL1001 ophthalmic solution
- Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular PainCompletedPhase 2Sylentis, S.A.NCT02455999Written as SYL1001
- Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular PainCompletedPhase 1/2Sylentis, S.A.NCT01776658Written as SYL1001
- Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy VolunteersCompletedPhase 1Sylentis, S.A.NCT01438281Written as SYL1001
Codes
What other systems call tivanisiran · ClinicalTrials.gg INT014482
- UNII (FDA) 2H47U2SBVOTIVANISIRANOne source FDA
- NCI Thesaurus C152665TivanisiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 2H47U2SBVO | TIVANISIRAN | One source FDA |
| NCI Thesaurus | C152665 | Tivanisiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.